Last reviewed · How we verify
NCT02865239: EFIMED
Feasibility Study of Breast MRI in Decubitus Position
NA trial testing Position for the 3.0 Tesla in Magnetic Resonance Imaging in Breast Cancer in 15 participants. Completed in 20 August 2015.
20 August 2015
Quick facts
| Lead sponsor | Institut de Cancérologie de Lorraine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 15 |
| Start date | 25 June 2015 |
| Primary completion | 20 August 2015 |
| Estimated completion | 20 August 2015 |
| Sites | 1 location across France |
Drugs / interventions tested
- Position for the 3.0 Tesla in Magnetic Resonance Imaging
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Institut de Cancérologie de Lorraine — full company profile →
Who can join
Under 18, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast MRI is performed in prone position which causes a number of questions. Indeed, the correlation with mammography and echography and the identification of preoperative lesions can be complex as echography and surgery are carried in supine position while mammography is performed in standing position. Moreover, the prone position is often considered as uncomfortable by the patients. However, there is few publications in the literature on breast MRI in decubitus position.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02865239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Institut de Cancérologie de Lorraine trials
Trials by the same sponsor.
- NCT07326800 — Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cance · NA · recruiting
- NCT07089485 — Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees · NA · not yet recruiting
- NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
- NCT06884332 — Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality · NA · recruiting
- NCT06903104 — Acceptability and Feasibility of a Stress Prevention Program Based on Meditation and Acceptance and Commitment Therapy f · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02865239 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Cancérologie de Lorraine
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02865239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing